Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Avadel AVDL -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (140)	8/3/2007 5:52:54 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 240

GSK now has CR in first position detailing by 2,000 reps. I assume that carries financial incentives to drive sales production. I believe you get what you incent. So that should help increase sales. FLML has a slide on it's web site that indicates a study of CR vs IR resulted in a 24% reduction in AE's in the CR arm. That sounds interesting. If those AE's are serious and the study is confirmed in other studies or in the observations of the practicing MD's it will drive sales of CR even in the face of generics. ij